KR20220150448A - Illite microparticles coated with polyvinylpyrrolidone having improved water dispersibility, preparation method thereof and use thereof - Google Patents
Illite microparticles coated with polyvinylpyrrolidone having improved water dispersibility, preparation method thereof and use thereof Download PDFInfo
- Publication number
- KR20220150448A KR20220150448A KR1020210056555A KR20210056555A KR20220150448A KR 20220150448 A KR20220150448 A KR 20220150448A KR 1020210056555 A KR1020210056555 A KR 1020210056555A KR 20210056555 A KR20210056555 A KR 20210056555A KR 20220150448 A KR20220150448 A KR 20220150448A
- Authority
- KR
- South Korea
- Prior art keywords
- illite
- polyvinylpyrrolidone
- coated
- microparticles
- genus
- Prior art date
Links
- 229910052900 illite Inorganic materials 0.000 title claims abstract description 109
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 title claims abstract description 100
- 229920000036 polyvinylpyrrolidone Polymers 0.000 title claims abstract description 100
- 239000001267 polyvinylpyrrolidone Substances 0.000 title claims abstract description 99
- 239000011859 microparticle Substances 0.000 title claims abstract description 59
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title claims abstract description 38
- VGIBGUSAECPPNB-UHFFFAOYSA-L nonaaluminum;magnesium;tripotassium;1,3-dioxido-2,4,5-trioxa-1,3-disilabicyclo[1.1.1]pentane;iron(2+);oxygen(2-);fluoride;hydroxide Chemical compound [OH-].[O-2].[O-2].[O-2].[O-2].[O-2].[F-].[Mg+2].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[K+].[K+].[K+].[Fe+2].O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2.O1[Si]2([O-])O[Si]1([O-])O2 VGIBGUSAECPPNB-UHFFFAOYSA-L 0.000 title claims description 105
- 238000002360 preparation method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 57
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 22
- 239000001301 oxygen Substances 0.000 claims abstract description 22
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 22
- 230000000844 anti-bacterial effect Effects 0.000 claims abstract description 21
- 235000013305 food Nutrition 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 13
- 239000002537 cosmetic Substances 0.000 claims abstract description 12
- 229940079593 drug Drugs 0.000 claims abstract description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 239000004566 building material Substances 0.000 claims abstract description 5
- 238000010276 construction Methods 0.000 claims abstract description 5
- 239000004035 construction material Substances 0.000 claims abstract description 5
- 201000010099 disease Diseases 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 239000004480 active ingredient Substances 0.000 claims description 15
- 208000024891 symptom Diseases 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 208000024827 Alzheimer disease Diseases 0.000 claims description 5
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 5
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 5
- 206010028980 Neoplasm Diseases 0.000 claims description 5
- 208000018737 Parkinson disease Diseases 0.000 claims description 5
- 208000006011 Stroke Diseases 0.000 claims description 5
- 208000025865 Ulcer Diseases 0.000 claims description 5
- 208000027418 Wounds and injury Diseases 0.000 claims description 5
- 230000032683 aging Effects 0.000 claims description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 5
- 206010003246 arthritis Diseases 0.000 claims description 5
- 201000011510 cancer Diseases 0.000 claims description 5
- 230000001684 chronic effect Effects 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 208000019622 heart disease Diseases 0.000 claims description 5
- 230000004054 inflammatory process Effects 0.000 claims description 5
- 208000028867 ischemia Diseases 0.000 claims description 5
- 208000019423 liver disease Diseases 0.000 claims description 5
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 5
- 208000017520 skin disease Diseases 0.000 claims description 5
- 231100000397 ulcer Toxicity 0.000 claims description 5
- 241000588724 Escherichia coli Species 0.000 claims description 4
- 241000588748 Klebsiella Species 0.000 claims description 4
- 241000589516 Pseudomonas Species 0.000 claims description 4
- 230000000845 anti-microbial effect Effects 0.000 claims description 4
- 235000013361 beverage Nutrition 0.000 claims description 4
- 235000009508 confectionery Nutrition 0.000 claims description 4
- 239000006210 lotion Substances 0.000 claims description 4
- 239000003642 reactive oxygen metabolite Substances 0.000 claims description 4
- 241000186216 Corynebacterium Species 0.000 claims description 3
- 241000194033 Enterococcus Species 0.000 claims description 3
- 241000588769 Proteus <enterobacteria> Species 0.000 claims description 3
- 241000194017 Streptococcus Species 0.000 claims description 3
- 235000013343 vitamin Nutrition 0.000 claims description 3
- 239000011782 vitamin Substances 0.000 claims description 3
- 229940088594 vitamin Drugs 0.000 claims description 3
- 229930003231 vitamin Natural products 0.000 claims description 3
- 208000002874 Acne Vulgaris Diseases 0.000 claims description 2
- 206010003645 Atopy Diseases 0.000 claims description 2
- 241000193830 Bacillus <bacterium> Species 0.000 claims description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 2
- 201000004624 Dermatitis Diseases 0.000 claims description 2
- 208000012641 Pigmentation disease Diseases 0.000 claims description 2
- 241000186429 Propionibacterium Species 0.000 claims description 2
- 201000004681 Psoriasis Diseases 0.000 claims description 2
- 241000191940 Staphylococcus Species 0.000 claims description 2
- 206010000496 acne Diseases 0.000 claims description 2
- 235000013334 alcoholic beverage Nutrition 0.000 claims description 2
- 239000003708 ampul Substances 0.000 claims description 2
- 208000010668 atopic eczema Diseases 0.000 claims description 2
- 235000008429 bread Nutrition 0.000 claims description 2
- 235000019219 chocolate Nutrition 0.000 claims description 2
- 239000006071 cream Substances 0.000 claims description 2
- 235000013365 dairy product Nutrition 0.000 claims description 2
- 239000000686 essence Substances 0.000 claims description 2
- 235000015243 ice cream Nutrition 0.000 claims description 2
- 235000013372 meat Nutrition 0.000 claims description 2
- 235000012149 noodles Nutrition 0.000 claims description 2
- 235000013550 pizza Nutrition 0.000 claims description 2
- 235000013580 sausages Nutrition 0.000 claims description 2
- 230000009759 skin aging Effects 0.000 claims description 2
- 235000011888 snacks Nutrition 0.000 claims description 2
- 235000014347 soups Nutrition 0.000 claims description 2
- 235000013616 tea Nutrition 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 230000037373 wrinkle formation Effects 0.000 claims description 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 2
- 206010052428 Wound Diseases 0.000 claims 2
- 241001122767 Theaceae Species 0.000 claims 1
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 15
- 230000002000 scavenging effect Effects 0.000 abstract description 5
- 239000000243 solution Substances 0.000 description 15
- 239000011248 coating agent Substances 0.000 description 7
- 238000000576 coating method Methods 0.000 description 7
- 239000002245 particle Substances 0.000 description 7
- 239000007787 solid Substances 0.000 description 6
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- -1 malitol Chemical compound 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 239000006137 Luria-Bertani broth Substances 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000002609 medium Substances 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 244000299461 Theobroma cacao Species 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000005784 autoimmunity Effects 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical compound OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229910018557 Si O Inorganic materials 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 238000000026 X-ray photoelectron spectrum Methods 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000002734 clay mineral Substances 0.000 description 1
- 238000001246 colloidal dispersion Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910001385 heavy metal Inorganic materials 0.000 description 1
- 208000026278 immune system disease Diseases 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 238000001878 scanning electron micrograph Methods 0.000 description 1
- LIVNPJMFVYWSIS-UHFFFAOYSA-N silicon monoxide Inorganic materials [Si-]#[O+] LIVNPJMFVYWSIS-UHFFFAOYSA-N 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 239000002341 toxic gas Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000011345 viscous material Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
- C08J3/00—Processes of treating or compounding macromolecular substances
- C08J3/12—Powdering or granulating
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
- A01N25/26—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests in coated particulate form
- A01N25/28—Microcapsules or nanocapsules
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/16—Inorganic salts, minerals or trace elements
- A23L33/165—Complexes or chelates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/19—Cosmetics or similar toiletry preparations characterised by the composition containing inorganic ingredients
- A61K8/26—Aluminium; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/81—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds obtained by reactions involving only carbon-to-carbon unsaturated bonds
- A61K8/817—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions or derivatives of such polymers, e.g. vinylimidazol, vinylcaprolactame, allylamines (Polyquaternium 6)
- A61K8/8182—Copolymers of vinyl-pyrrolidones. Compositions of derivatives of such polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- C—CHEMISTRY; METALLURGY
- C01—INORGANIC CHEMISTRY
- C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
- C01B33/00—Silicon; Compounds thereof
- C01B33/20—Silicates
- C01B33/36—Silicates having base-exchange properties but not having molecular sieve properties
- C01B33/38—Layered base-exchange silicates, e.g. clays, micas or alkali metal silicates of kenyaite or magadiite type
- C01B33/42—Micas ; Interstratified clay-mica products
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K3/00—Use of inorganic substances as compounding ingredients
- C08K3/34—Silicon-containing compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L39/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by a single or double bond to nitrogen or by a heterocyclic ring containing nitrogen; Compositions of derivatives of such polymers
- C08L39/04—Homopolymers or copolymers of monomers containing heterocyclic rings having nitrogen as ring member
- C08L39/06—Homopolymers or copolymers of N-vinyl-pyrrolidones
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/302—Foods, ingredients or supplements having a functional effect on health having a modulating effect on age
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/322—Foods, ingredients or supplements having a functional effect on health having an effect on the health of the nervous system or on mental function
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/326—Foods, ingredients or supplements having a functional effect on health having effect on cardiovascular health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/3262—Foods, ingredients or supplements having a functional effect on health having an effect on blood cholesterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/15—Inorganic Compounds
- A23V2250/156—Mineral combination
- A23V2250/1638—Undefined mineral extract
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/60—Particulates further characterized by their structure or composition
- A61K2800/61—Surface treated
- A61K2800/62—Coated
- A61K2800/624—Coated by macromolecular compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
- C08K2201/00—Specific properties of additives
- C08K2201/002—Physical properties
- C08K2201/005—Additives being defined by their particle size in general
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Inorganic Chemistry (AREA)
- Polymers & Plastics (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Birds (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Agronomy & Crop Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
Abstract
Description
본 발명은 수분산성이 향상된 폴리비닐파이롤리돈 코팅 일라이트 마이크로 입자, 이의 제조 방법 및 이의 용도에 관한 것이다. 본 발명에 따른 수분산성이 향상된 폴리비닐파이롤리돈(polyvinylpyrrolidone, PVP) 코팅 일라이트 마이크로 입자(PVP-illite microparticles; P-lite)는 활성산소제거 능력 및 항균 활성이 뛰어나고 안정적이므로, 화장료 조성물, 약제학적 조성물, 의약외품 조성물 및 식품 조성물뿐만 아니라, 의료기구, 건설/건축 자재, 자동차 부품, 선박 부품, 철도 부품, 스포츠 용품 또는 완구 용품에 사용될 수 있을 것으로 기대된다. The present invention relates to polyvinylpyrrolidone-coated illite microparticles with improved water dispersibility, a method for preparing the same, and a use thereof. Polyvinylpyrrolidone (PVP) coated illite microparticles (PVP-illite microparticles; P-lite) with improved water dispersibility according to the present invention are excellent in active oxygen removal ability and antibacterial activity and are stable, so cosmetic compositions, pharmaceuticals It is expected to be used not only for medical compositions, quasi-drug compositions and food compositions, but also for medical devices, construction/building materials, automobile parts, ship parts, railway parts, sports goods, or toy goods.
일라이트는 다공성 운모류 천연 점토광물로서 일반적으로 (K,H3O)(Al,Mg,Fe)2(Si,Al)4O10((OH)2,H2O)의 화학조성을 갖고 있으며 얇은 쉬트 구조가 특징이고, 다른 천연광물 대비 높은 흡착성, 탄성을 나타낸다. 일라이트는 전 세계적으로 미국의 펜실베니아주, 일리노이주, 중국 사천성 지역, 캐나다 퀘벡주 및 그리고 호주 등에서 발견되고 있으며, 국내에서는 충북 영동군에 최대 5억톤의 매장량이 추정되고 있다. 일라이트는 타 광물대비 탁월한 원적외선 방출효과, 항균 효과, 중금속 및 유독가스 흡착 및 탈취를 통한 정화기능등 실생활에 적용되는 제품뿐만 아니라 산업적으로도 매우 큰 응용가능성을 갖고 있다. Illite is a porous mica natural clay mineral that generally has a chemical composition of (K,H 3 O)(Al,Mg,Fe) 2 (Si,Al) 4 O 10 ((OH) 2 ,H 2 O) and has a thin It is characterized by a sheet structure and exhibits high adsorption and elasticity compared to other natural minerals. Illite is found worldwide in Pennsylvania and Illinois in the US, Sichuan in China, Quebec in Canada, and Australia. Illite has a very large potential for industrial applications as well as products applied to real life, such as excellent far-infrared emission effect compared to other minerals, antibacterial effect, and purification function through adsorption and deodorization of heavy metals and toxic gases.
그러나, 일라이트가 발현하는 우수한 기능을 효과적으로 발휘하기 위해서는 일정 크기 수준 이하의 콜로이드 분산 상태로 제조하는 것이 요구되며, 이를 통해 건강 및 미용용품, 및 산업원료로서의 적용이 가능하다. 따라서 일라이트의 물분산성(water-dispersibility) 특성 향상을 위한 다양한 연구가 시도되고 있다. However, in order to effectively exhibit the excellent function expressed by illite, it is required to prepare it in a colloidal dispersion state of a certain size level or less, and through this, it is possible to apply it as health and beauty products and industrial raw materials. Therefore, various studies have been attempted to improve the water-dispersibility characteristics of illite.
본 발명자들은 일라이트의 수분산성을 향상시키기 위하여 예의 노력한 결과, 고분자로서 폴리비닐파이롤리돈(polyvinylpyrrolidone, PVP)를 사용하여 일라이트를 코팅하는 경우, 일라이트의 수분산성이 향상되어 활성산소제거 능력 및 항균 활성이 현저히 증가할 수 있음을 확인한 후, 본 발명을 완성하기에 이르렀다. As a result of the inventors' efforts to improve the water dispersibility of illite, when coating illite using polyvinylpyrrolidone (PVP) as a polymer, the water dispersibility of illite is improved to remove active oxygen. And after confirming that the antimicrobial activity can be remarkably increased, the present invention has been completed.
본 발명은 수분산성이 향상된 폴리비닐파이롤리돈(polyvinylpyrrolidone, PVP) 코팅 일라이트 마이크로 입자를 제공하는 것을 목적으로 한다. An object of the present invention is to provide polyvinylpyrrolidone (PVP)-coated illite microparticles with improved water dispersibility.
본 발명은 또한 (a) 용매에 폴리비닐파이롤리돈(polyvinylpyrrolidone, PVP)를 첨가하여 PVP 용액을 제조하는 단계; 및 (b) 상기 PVP 용액에 일라이트를 첨가하여 반응시키는 단계를 포함하는 일라이트의 수분산성 향상 방법을 제공하는 것을 목적으로 한다. The present invention also provides (a) preparing a PVP solution by adding polyvinylpyrrolidone (PVP) to a solvent; and (b) adding illite to the PVP solution to react.
본 발명은 또한 수분산성이 향상된 폴리비닐파이롤리돈 코팅 일라이트 마이크로 입자를 유효성분으로 포함하는 화장료 조성물을 제공하는 것을 목적으로 한다. Another object of the present invention is to provide a cosmetic composition comprising polyvinylpyrrolidone-coated illite microparticles with improved water dispersibility as an active ingredient.
본 발명은 또한 수분산성이 향상된 폴리비닐파이롤리돈 코팅 일라이트 마이크로 입자를 유효성분으로 포함하는 약제학적 조성물을 제공하는 것을 목적으로 한다. Another object of the present invention is to provide a pharmaceutical composition comprising polyvinylpyrrolidone-coated illite microparticles having improved water dispersibility as an active ingredient.
본 발명은 또한 수분산성이 향상된 폴리비닐파이롤리돈 코팅 일라이트 마이크로 입자를 유효성분으로 포함하는 의약외품 조성물을 제공하는 것을 목적으로 한다. Another object of the present invention is to provide a quasi-drug composition comprising polyvinylpyrrolidone-coated illite microparticles having improved water dispersibility as an active ingredient.
본 발명은 또한 수분산성이 향상된 폴리비닐파이롤리돈 코팅 일라이트 마이크로 입자를 유효성분으로 포함하는 식품 조성물을 제공하는 것을 목적으로 한다. Another object of the present invention is to provide a food composition comprising polyvinylpyrrolidone-coated illite microparticles having improved water dispersibility as an active ingredient.
본 발명은 또한 수분산성이 향상된 폴리비닐파이롤리돈 코팅 일라이트 마이크로 입자를 유효성분으로 포함하는 항균 조성물을 제공하는 것을 목적으로 한다. Another object of the present invention is to provide an antibacterial composition comprising polyvinylpyrrolidone-coated illite microparticles having improved water dispersibility as an active ingredient.
본 발명에 따른 수분산성이 향상된 폴리비닐파이롤리돈(polyvinylpyrrolidone, PVP) 코팅 일라이트 마이크로 입자(PVP-illite microparticles; P-lite)는 활성산소제거 능력 및 항균 활성이 뛰어나고 안정적이므로, 화장료 조성물, 약제학적 조성물, 의약외품 조성물 및 식품 조성물뿐만 아니라, 의료기구, 건설/건축 자재, 자동차 부품, 선박 부품, 철도 부품, 스포츠 용품 또는 완구 용품에 사용될 수 있을 것으로 기대된다. Polyvinylpyrrolidone (PVP) coated illite microparticles (PVP-illite microparticles; P-lite) with improved water dispersibility according to the present invention are excellent in active oxygen removal ability and antibacterial activity and are stable, so cosmetic compositions, pharmaceuticals It is expected to be used not only for medical compositions, quasi-drug compositions and food compositions, but also for medical devices, construction/building materials, automobile parts, ship parts, railway parts, sports goods, or toy goods.
도 1은 본 발명에 따른 일라이트 및 폴리비닐파이롤리돈(polyvinylpyrrolidone, PVP)의 화학 구조를 나타낸다.
도 2는 본 발명에 따른 수분산성이 향상된 폴리비닐파이롤리돈(polyvinylpyrrolidone, PVP) 코팅 일라이트 마이크로 입자의 모식도를 나타낸다 .
도 3은 실시예 1에 따른 일라이트 및 PVP 코팅 일라이트 마이크로 입자(P-lite)의 크기를 나타낸다.
도 4는 실시예 1에 따른 일라이트 및 PVP 코팅 일라이트 마이크로 입자(P-lite)의 크기 분포도를 나타낸다.
도 5는 실시예 1에 따른 일라이트 및 PVP 코팅 일라이트 마이크로 입자(P-lite)의 SEM 사진을 나타낸다.
도 6은 실시예 1에 따른 일라이트 및 PVP 코팅 일라이트 마이크로 입자(P-lite)의 FTIR spectra를 나타낸다.
도 7은 실시예 1에 따른 일라이트 및 PVP 코팅 일라이트 마이크로 입자(P-lite)의 XPS spectra를 나타낸다.
도 8은 실시예 2에 따른 일라이트 및 PVP 코팅 일라이트 마이크로 입자(P-lite)의 동결건조 안정성을 나타낸다.
도 9는 실시예 2에 따른 일라이트 및 PVP 코팅 일라이트 마이크로 입자(P-lite)의 PBS내 크기 변화를 나타낸다.
도 10은 실험예 1에 따른 일라이트 및 PVP 코팅 일라이트 마이크로 입자(P-lite)의 OH·활성산소제거 능력을 나타낸다.
도 11은 실험예 2에 따른 일라이트 및 PVP 코팅 일라이트 마이크로 입자(P-lite)의 S.aureus에 대한 항균 활성을 나타낸다. 1 shows the chemical structures of illite and polyvinylpyrrolidone (PVP) according to the present invention.
Figure 2 shows a schematic diagram of polyvinylpyrrolidone (PVP) coated illite microparticles with improved water dispersibility according to the present invention.
3 shows the size of illite and PVP-coated illite microparticles (P-lite) according to Example 1.
Figure 4 shows the size distribution of illite and PVP-coated illite micro-particles (P-lite) according to Example 1.
5 shows SEM images of illite and PVP-coated illite microparticles (P-lite) according to Example 1.
6 shows FTIR spectra of illite and PVP-coated illite microparticles (P-lite) according to Example 1.
7 shows XPS spectra of illite and PVP-coated illite microparticles (P-lite) according to Example 1.
8 shows the freeze-drying stability of illite and PVP-coated illite microparticles (P-lite) according to Example 2.
Figure 9 shows the size change in PBS of illite and PVP-coated illite microparticles (P-lite) according to Example 2.
10 shows the OH · active oxygen removal ability of illite and PVP-coated illite microparticles (P-lite) according to Experimental Example 1.
11 shows the antibacterial activity of illite and PVP-coated illite microparticles (P-lite) against S. aureus according to Experimental Example 2.
이하, 발명의 구체적인 구현예에 따른 수분산성이 향상된 폴리비닐파이롤리돈 코팅 일라이트 마이크로 입자, 이의 제조 방법 및 이의 용도에 대하여 상세하게 설명하기로 한다. 다만, 이는 발명의 하나의 예시로서 제시되는 것으로, 이에 의해 발명의 권리범위가 한정되는 것은 아니며, 발명의 권리범위 내에서 구현예에 대한 다양한 변형이 가능함은 당업자에게 자명하다. 본 명세서 전체에서 특별한 언급이 없는 한 "포함" 또는 "함유"라 함은 어떤 구성 요소(또는 구성 성분)를 별다른 제한 없이 포함함을 지칭하며, 다른 구성 요소(또는 구성 성분)의 부가를 제외하는 것으로 해석될 수 없다.Hereinafter, polyvinylpyrrolidone-coated illite microparticles with improved water dispersibility according to specific embodiments of the present invention, a method for preparing the same, and a use thereof will be described in detail. However, this is presented as an example of the invention, whereby the scope of the invention is not limited, and it is obvious to those skilled in the art that various modifications to the embodiments are possible within the scope of the invention. Throughout this specification, unless otherwise specified, "include" or "include" refers to including a certain component (or component) without particular limitation, and excludes the addition of other components (or components). cannot be interpreted as
제1구현예에 따르면, According to the first embodiment,
본 발명은 수분산성이 향상된 폴리비닐파이롤리돈(polyvinylpyrrolidone, PVP) 코팅 일라이트 마이크로 입자를 제공하고자 한다. 본 발명에서 사용된 폴리비닐파이롤리돈(PVP) 및 일리아트의 화학 구조를 도 1에 나타내었다. The present invention is to provide polyvinylpyrrolidone (PVP)-coated illite microparticles with improved water dispersibility. The chemical structures of polyvinylpyrrolidone (PVP) and illiat used in the present invention are shown in FIG. 1.
본 발명에 따른 폴리비닐파이롤리돈 코팅 일라이트 마이크로 입자에 있어서, 상기 폴리비닐파이롤리돈 및 일라이트의 중량비는 1:1 내지 1:20인 것을 특징으로 한다. 바람직하기는, 상기 폴리비닐파이롤리돈 및 일라이트의 중량비는 1:5인 것을 특징으로 한다. In the polyvinylpyrrolidone-coated illite microparticles according to the present invention, the weight ratio of the polyvinylpyrrolidone and illite is 1:1 to 1:20. Preferably, the weight ratio of the polyvinylpyrrolidone and illite is 1:5.
본 발명에 따른 폴리비닐파이롤리돈 코팅 일라이트 마이크로 입자에 있어서, 상기 폴리비닐파이롤리돈의 분자량은 10kDa인 것을 특징으로 한다. In the polyvinylpyrrolidone-coated illite microparticles according to the present invention, the molecular weight of the polyvinylpyrrolidone is characterized in that 10kDa.
본 발명에 따른 폴리비닐파이롤리돈 코팅 일라이트 마이크로 입자에 있어서, 상기 폴리비닐파이롤리돈 코팅 일라이트 마이크로 입자의 크기는 4μm 내지 9μm인 것을 특징으로 한다. In the polyvinylpyrrolidone-coated illite microparticles according to the present invention, the polyvinylpyrrolidone-coated illite microparticles are characterized in that the size is 4 μm to 9 μm.
본 발명에 따른 폴리비닐파이롤리돈 코팅 일라이트 마이크로 입자에 있어서, 상기 폴리비닐파이롤리돈 코팅 일라이트 마이크로 입자는 활성산소제거 능력을 갖는 것을 특징으로 한다. In the polyvinylpyrrolidone-coated illite microparticles according to the present invention, the polyvinylpyrrolidone-coated illite microparticles are characterized in that they have an active oxygen scavenging ability.
본 발명에 따른 폴리비닐파이롤리돈 코팅 일라이트 마이크로 입자에 있어서, 상기 폴리비닐파이롤리돈 코팅 일라이트 마이크로 입자는 황색포도상구균(Staphylococcus aureus)에 대하여 항균활성을 갖는 것을 특징으로 한다. In the polyvinylpyrrolidone-coated illite microparticles according to the present invention, the polyvinylpyrrolidone-coated illite microparticles are characterized in that they have antibacterial activity against Staphylococcus aureus .
제2구현예에 따르면, According to the second embodiment,
본 발명은 (a) 용매에 폴리비닐파이롤리돈(polyvinylpyrrolidone, PVP)를 첨가하여 PVP 용액을 제조하는 단계; 및 (b) 상기 PVP 용액에 일라이트를 첨가하여 반응시키는 단계를 포함하는 일라이트의 수분산성 향상 방법을 제공하고자 한다. 본 발명에 따른 일라이트의 수분산성 향상 방법의 모식도를 도 2에 나타내었다. The present invention comprises the steps of (a) preparing a PVP solution by adding polyvinylpyrrolidone (PVP) to a solvent; And (b) to provide a method for improving the water dispersibility of illite comprising adding illite to the PVP solution and reacting. A schematic diagram of a method for improving the water dispersibility of illite according to the present invention is shown in FIG.
본 발명에 따른 일라이트의 수분산성 향상 방법에 있어서, 상기 용매는 증류수 또는 에탄올인 것을 특징으로 한다. In the method for improving the water dispersibility of illite according to the present invention, the solvent is characterized in that distilled water or ethanol.
본 발명에 따른 일라이트의 수분산성 향상 방법에 있어서, 상기 폴리비닐파이롤리돈 및 일라이트의 중량비는 1:1 내지 1:20인 것을 특징으로 한다. In the method for improving the water dispersibility of illite according to the present invention, the weight ratio of the polyvinylpyrrolidone and illite is 1:1 to 1:20.
본 발명에 따른 일라이트의 수분산성 향상 방법에 있어서, 상기 반응은 4℃에서 8 내지 12시간 동안 이루어지는 것을 특징으로 한다. In the method for improving the water dispersibility of illite according to the present invention, the reaction is characterized in that it is performed at 4 ℃ for 8 to 12 hours.
본 발명에 따른 일라이트의 수분산성 향상 방법에 있어서, 상기 방법은 (c) PVP 용액과 반응이 이루어진 일라이트를 건조시키는 단계를 추가로 포함하는 것을 특징으로 한다. In the method for improving the water dispersibility of illite according to the present invention, the method is characterized by further comprising the step of (c) drying the illite having reacted with the PVP solution.
제3구현에에 따르면, According to the third embodiment,
본 발명은 수분산성이 향상된 폴리비닐파이롤리돈 코팅 일라이트 마이크로 입자를 유효성분으로 포함하는 활성산소로 유발되는 증상 또는 질환의 예방 또는 개선용 화장료 조성물을 제공하고자 한다. The present invention is to provide a cosmetic composition for the prevention or improvement of symptoms or diseases caused by active oxygen containing polyvinylpyrrolidone-coated illite microparticles with improved water dispersibility as an active ingredient.
본 발명에 따른 화장료 조성물에 있어서, 상기 활성산소로 유발되는 증상 또는 질환은 피부노화, 주름생성, 피부색소침착, 아토피, 여드름, 건선 또는 습진인 것을 특징으로 한다.In the cosmetic composition according to the present invention, the symptom or disease caused by the active oxygen is characterized in that skin aging, wrinkle formation, skin pigmentation, atopy, acne, psoriasis or eczema.
본 발명에 따른 화장료 조성물에 있어서, 상기 폴리비닐파이롤리돈 및 일라이트의 중량비는 1:1 내지 1:20인 것을 특징으로 한다. In the cosmetic composition according to the present invention, the weight ratio of the polyvinylpyrrolidone and illite is 1:1 to 1:20.
본 발명에 따른 화장료 조성물에 있어서, 상기 화장료는 앰플, 크림, 로션, 화장수, 에센스 또는 팩의 형태로 제조되는 것을 특징으로 한다. In the cosmetic composition according to the present invention, the cosmetic is characterized in that it is prepared in the form of an ampoule, cream, lotion, lotion, essence or pack.
제4구현예에 따르면, According to the fourth embodiment,
본 발명은 수분산성이 향상된 폴리비닐파이롤리돈 코팅 일라이트 마이크로 입자를 유효성분으로 포함하는 활성산소로 유발되는 증상 또는 질환의 예방 또는 치료용 약제학적 조성물을 제공하고자 한다. An object of the present invention is to provide a pharmaceutical composition for preventing or treating symptoms or diseases caused by active oxygen, including polyvinylpyrrolidone-coated illite microparticles having improved water dispersibility as an active ingredient.
본 발명에 따른 약제학적 조성물에 있어서, 상기 활성산소 과잉생성으로 인해 유발되는 질환은 뇌졸중, 파킨슨병, 알츠하이머병, 노화, 심장질환, 허혈, 동맥경화, 피부질환, 염증, 관절염, 류마티스 관절염, 자가면역질환, 고지혈증, 간질환, 당뇨병, 암, 만성궤양, 화상 또는 창상인 것을 특징으로 한다.In the pharmaceutical composition according to the present invention, diseases caused by excessive production of reactive oxygen species are stroke, Parkinson's disease, Alzheimer's disease, aging, heart disease, ischemia, arteriosclerosis, skin disease, inflammation, arthritis, rheumatoid arthritis, autologous It is characterized by immune disease, hyperlipidemia, liver disease, diabetes, cancer, chronic ulcer, burn or wound.
본 발명에 따른 약제학적 조성물에 있어서, 상기 폴리비닐파이롤리돈 및 일라이트의 중량비는 1:1 내지 1:20인 것을 특징으로 한다. In the pharmaceutical composition according to the present invention, the weight ratio of polyvinylpyrrolidone and illite is characterized in that 1:1 to 1:20.
본 발명에 따른 약제학적 조성물은 일반적인 경구 또는 비경구 투여 방법으로 환자에게 투여될 수 있으며, 고체 또는 액체 형태 어떠한 형태로도 가능하다. 또한, 본 발명에 따른 약제학적 조성물은 약제학적으로 허용 가능한 1종 이상의 액체 또는 고체 담체를 더 포함할 수 있다. 또한 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. 상기 고체 형태의 제제에는 정제, 환제, 산제, 과립제, 캡슐제, 펠렛제, 세립제 또는 분제일 수 있으며, 이러한 고형제제는 상기 복합체에 담체, 부형제 및/또는 희석제를 첨가하여 조제할 수 있다. 상기 담체, 부형제 및/또는 희석제로는 락토오스(lactose), 수크로오스(sucrose), 덱스트로오스(dextrose), 만니톨(mannitol), 말리톨(malitol), 소르비톨(sorbitol), 자일리톨(xylitol), 에리트리톨(erithritol), 전분(starch), 아카시아고무(acacia rubber), 알지네이트(alginate), 젤라틴(gelatin), 칼슘 포스페이트(calcium phosphate), 칼슘 실리케이트(calcium silicate), 셀룰로오스(cellulose), 폴리비닐 피롤리돈(polyvinyl pyrrolidone), 마그네슘 스테아레이트(magnesium stearate) 및 광물유 등이 있다. 상기 액체 형태의 제제는 용액, 현탁액 또는 유탁액일 수 있으며, 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다. 경구용으로 적당한 수성 현탁제로는 미분된 활성 성분을 천연 또는 합성검, 수지, 메틸셀룰로오스(methyl cellulose), 소디움카르복시메틸셀룰로오스(Sodium carboxymethyl cellulose) 및 공지의 현탁제와 같은 점성 물질에 분산시켜 제조될 수 있다. 비경구 투여제로는 주사제, 점적제, 수액, 연고, 스프레이제, 현탁제, 유제, 좌제 등을 들 수 있다. 비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제 및 좌제가 포함된다. 비수성용제, 현탁제로는 프로필렌글리콜(propylene glycol), 폴리에틸렌글리콜(polyethylene glycol), 올리브 오일과 같은 식물성 오일, 에틸올레이트(ethyl oleate)와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골(macrogol), 카카오지, 라우린지, 글리세로젤라틴(glycerogelatin) 등이 사용될 수 있다.The pharmaceutical composition according to the present invention may be administered to a patient by a general oral or parenteral administration method, and may be in any solid or liquid form. In addition, the pharmaceutical composition according to the present invention may further include one or more pharmaceutically acceptable liquid or solid carriers. In addition, it may be prepared using diluents or excipients such as commonly used fillers, extenders, binders, wetting agents, disintegrants, and surfactants. The solid formulations may be tablets, pills, powders, granules, capsules, pellets, fine granules or powders, and these solid formulations may be prepared by adding carriers, excipients and/or diluents to the complex. Examples of the carrier, excipient and/or diluent include lactose, sucrose, dextrose, mannitol, malitol, sorbitol, xylitol, erythritol (erithritol), starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, polyvinyl pyrrolidone (polyvinyl pyrrolidone), magnesium stearate and mineral oil. The liquid formulation may be a solution, suspension, or emulsion, and may include various excipients such as wetting agents, sweeteners, aromatics, and preservatives in addition to water and liquid paraffin, which are commonly used simple diluents. Aqueous suspensions suitable for oral use may be prepared by dispersing the finely divided active ingredient in a viscous material such as natural or synthetic gums, resins, methyl cellulose, sodium carboxymethyl cellulose and other known suspending agents. can Examples of parenteral administration include injections, drops, infusions, ointments, sprays, suspensions, emulsions, suppositories, and the like. Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solvents, suspensions, emulsions, freeze-dried formulations, and suppositories. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents. As a base material for suppositories, witepsol, macrogol, cacao butter, laurin paper, glycerogelatin, and the like may be used.
제5구현예에 따르면, According to the fifth embodiment,
본 발명은 수분산성이 향상된 폴리비닐파이롤리돈 코팅 일라이트 마이크로 입자를 유효성분으로 포함하는 활성산소로 유발되는 증상 또는 질환의 예방 또는 치료용 의약외품 조성물을 제공하고자 한다. The present invention is to provide a quasi-drug composition for preventing or treating symptoms or diseases caused by active oxygen, comprising as an active ingredient polyvinylpyrrolidone-coated illite microparticles having improved water dispersibility.
본 발명에 따른 의약외품 조성물에 있어서, 상기 활성산소 과잉생성으로 인해 유발되는 질환은 뇌졸중, 파킨슨병, 알츠하이머병, 노화, 심장질환, 허혈, 동맥경화, 피부질환, 염증, 관절염, 류마티스 관절염, 자가면역질환, 고지혈증, 간질환, 당뇨병, 암, 만성궤양, 화상 또는 창상인 것을 특징으로 한다.In the quasi-drug composition according to the present invention, diseases caused by excessive production of active oxygen include stroke, Parkinson's disease, Alzheimer's disease, aging, heart disease, ischemia, arteriosclerosis, skin disease, inflammation, arthritis, rheumatoid arthritis, autoimmunity It is characterized in that it is a disease, hyperlipidemia, liver disease, diabetes, cancer, chronic ulcer, burn or wound.
본 발명에 따른 의약외품 조성물에 있어서, 상기 폴리비닐파이롤리돈 및 일라이트의 중량비는 1:1 내지 1:20인 것을 특징으로 한다. In the quasi-drug composition according to the present invention, the weight ratio of the polyvinylpyrrolidone and illite is characterized in that 1:1 to 1:20.
본 발명에 따른 의약외품 조성물에 있어서, 상기 의약외품 조성물은 소독 청결제, 샤워폼, 가그린, 물티슈, 세제 비누, 핸드 워시, 가습기 충진제, 마스크, 연고제 또는 필터 충진제인 것을 특징으로 한다.In the quasi-drug composition according to the present invention, the quasi-drug composition is characterized in that it is a disinfectant cleanser, shower foam, gargreen, wet tissue, detergent soap, hand wash, humidifier filler, mask, ointment or filter filler.
제6구현예에 따르면, According to the sixth embodiment,
본 발명은 수분산성이 향상된 폴리비닐파이롤리돈 코팅 일라이트 마이크로 입자를 유효성분으로 포함하는 활성산소로 유발되는 증상 또는 질환의 예방 또는 개선용 식품조성물을 제공하고자 한다. The present invention is to provide a food composition for the prevention or improvement of symptoms or diseases caused by active oxygen containing polyvinylpyrrolidone-coated illite microparticles with improved water dispersibility as an active ingredient.
본 발명에 따른 식품 조성물에 있어서, 상기 활성산소 과잉생성으로 인해 유발되는 질환은 뇌졸중, 파킨슨병, 알츠하이머병, 노화, 심장질환, 허혈, 동맥경화, 피부질환, 염증, 관절염, 류마티스 관절염, 자가면역질환, 고지혈증, 간질환, 당뇨병, 암, 만성궤양, 화상 또는 창상인 것을 특징으로 한다.In the food composition according to the present invention, diseases caused by excessive production of reactive oxygen species are stroke, Parkinson's disease, Alzheimer's disease, aging, heart disease, ischemia, arteriosclerosis, skin disease, inflammation, arthritis, rheumatoid arthritis, autoimmunity It is characterized in that it is a disease, hyperlipidemia, liver disease, diabetes, cancer, chronic ulcer, burn or wound.
본 발명에 따른 식품 조성물에 있어서, 상기 폴리비닐파이롤리돈 및 일라이트의 중량비는 1:1 내지 1:20인 것을 특징으로 한다. In the food composition according to the present invention, the weight ratio of polyvinylpyrrolidone and illite is characterized in that 1:1 to 1:20.
본 발명에 따른 식품 조성물에 있어서, 상기 식품은 육류, 소세지, 빵, 쵸코렛, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 또는 비타민 복합제인 것을 특징으로 한다.In the food composition according to the present invention, the food is meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks , characterized in that it is an alcoholic beverage or a vitamin complex.
본 발명에 따른 식품 조성물에 있어서, 상기 식품 조성물은 여러 가지 영양제, 비타민, 전해질, 풍미제, 착색제, 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산 음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 본 발명의 조성물은 천연과일쥬스, 과일쥬스 음료 또는 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다.In the food composition according to the present invention, the food composition contains various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid and its salts, alginic acid and its salts, organic acids, protective colloidal thickeners, pH regulators, stabilizers, It may contain preservatives, glycerin, alcohol, carbonation agents used in carbonated beverages, and the like. In addition, the composition of the present invention may contain fruit flesh for preparing natural fruit juice, fruit juice beverage or vegetable beverage. These components may be used independently or in combination.
제7구현예에 따르면, According to the seventh embodiment,
본 발명은 수분산성이 향상된 폴리비닐파이롤리돈 코팅 일라이트 마이크로 입자를 포함하는 항균 조성물을 제공하고자 한다. The present invention is to provide an antibacterial composition comprising polyvinylpyrrolidone-coated illite microparticles with improved water dispersibility.
본 발명에 따른 항균 조성물에 있어서, 상기 폴리비닐파이롤리돈 및 일라이트의 중량비는 1:1 내지 1:20인 것을 특징으로 한다. In the antimicrobial composition according to the present invention, the weight ratio of the polyvinylpyrrolidone and illite is characterized in that 1:1 to 1:20.
본 발명에 따른 항균 조성물에 있어서, 상기 항균 조성물은 스타필로코커스(Staphylococcus) 속, 바실러스(Bacillus) 속, 슈도모나스(Pseudomonas) 속, 칸디다(Candida) 속, 프로피오니박테리움(Propionibacterium) 속, 스트렙토코커스(Streptococcus) 속, 프로테우스(Proteus) 속, 코리네박테리움(Corynebacterium) 속, 엔테로코커스(Enterococcus) 속, 클렙시엘라(Klebsiella) 속 및 대장균(Escherichia coli)에 항균 활성을 나타내는 것을 특징으로 한다.In the antibacterial composition according to the present invention, the antimicrobial composition is Staphylococcus genus, Bacillus genus, Pseudomonas genus, Pseudomonas genus, Candida genus, Propionibacterium genus, Streptococcus ( Streptococcus ), Proteus ( Proteus ), Corynebacterium ( Corynebacterium ), Enterococcus ( Enterococcus ), Klebsiella ( Klebsiella ) and Escherichia coli ( Escherichia coli ) It is characterized by showing antibacterial activity.
본 발명에 따른 항균 조성물에 있어서, 상기 항균 조성물은 의료기구, 건설/건축 자재, 자동차 부품, 선박 부품, 철도 부품, 스포츠 용품 또는 완구 용품에 사용되는 것을 특징으로 한다. In the antibacterial composition according to the present invention, the antibacterial composition is characterized in that it is used for medical devices, construction / building materials, automobile parts, ship parts, railway parts, sports goods or toy goods.
이하, 본 발명을 실시예 및 실험예에 의해 보다 상세히 설명한다. 단, 하기 실시예 및 실험예는 본 발명을 예시하는 것일 뿐, 본 발명의 내용이 하기 실시예 및 실험예에 한정되는 것은 아니다.Hereinafter, the present invention will be described in more detail by examples and experimental examples. However, the following Examples and Experimental Examples are merely illustrative of the present invention, and the contents of the present invention are not limited to the following Examples and Experimental Examples.
<실시예><Example>
실시예 1. PVP 코팅 일라이트 마이크로 입자(P-lite) 제조 및 특성평가Example 1. Manufacturing and characterization of PVP-coated illite microparticles (P-lite)
1-1. 실험 방법1-1. Experiment method
PVP (MW=10kDa; 0, 250, 500, 1000mg)를 5ml의 3차 증류수에 녹인 후, 각각의 PVP 고분자 용액에 50mg의 일라이트를 첨가하여, 하기의 표 1에 나타낸 PVP: Illite의 중량비를 갖는 반응용액을 생성하였다. 각 반응용액을 5분간 vortex mixer로 교반하고, 약 8 내지 12시간동안 4℃에서 rotatory shaker를 이용해 반응시킨 후, 3일간 동결 건조시켰다.After dissolving PVP (MW = 10 kDa; 0, 250, 500, 1000 mg) in 5 ml of tertiary distilled water, 50 mg of illite was added to each PVP polymer solution, and the weight ratio of PVP: Illite shown in Table 1 below was A reaction solution with Each reaction solution was stirred with a vortex mixer for 5 minutes, reacted using a rotatory shaker at 4° C. for about 8 to 12 hours, and then freeze-dried for 3 days.
1-2. P-lite의 크기 및 크기 분포도 확인1-2. Check the size and size distribution of P-lite
상기 제조된 PVP 코팅 일라이트 마이크로 입자의 크기 및 크기분포도를 Zetasizer (ELSZ-2000, Otsuka) 장비를 이용하여 분석하였다. 그 결과, 일라이트 대비 PVP 비율이 높을수록 P-lite 마이크로 입자의 크기가 증가하였으며(도 3), 약 4μm 내지 9μm의 P-lite 마이크로 입자가 균일하게 제조되는 것으로 확인되었다(도 4). The size and size distribution of the prepared PVP-coated illite microparticles were analyzed using Zetasizer (ELSZ-2000, Otsuka) equipment. As a result, as the ratio of PVP to illite increased, the size of P-lite microparticles increased (FIG. 3), and it was confirmed that P-lite microparticles of about 4 μm to 9 μm were uniformly produced (FIG. 4).
1-3. P-lite의 입자 형태 확인1-3. Check the particle shape of P-lite
상기 제조된 PVP 코팅 일라이트 마이크로 입자의 입자 형태를 SEM을 이용하여 분석하였다. 그 결과, 코팅 전 일라이트 입자와 비교해 PVP 코팅 후 입자의 크기가 증가했으며 표면이 매끄러워진 것으로 확인되었다(도 5).The particle shape of the prepared PVP-coated illite micro-particles was analyzed using SEM. As a result, it was confirmed that the size of the particles after PVP coating increased and the surface became smooth compared to the illite particles before coating (FIG. 5).
1-4. P-lite의 코팅 확인1-4. Check the coating of P-lite
상기 일라이트 입자에 PVP가 잘 코팅되어 있는지 여부를 알아보기 위하여 FTIR과 XPS를 이용하여 분석하였다. 그 결과, PVP 코팅 후 일라이트의 FTIR spectra에서 PVP의 amine peak이 관찰되었으며, 일라이트의 주성분인 Si-O에 해당하는 peak이 모든 P-lite의 spectra에서 970cm-1에 관찰되었다(도 6). 또한 PVP에서만 발견되는 조성인 N1s와 C1s가 P-lite의 spectra에서 관찰되었으며, 일라이트의 주 조성인 Si2s와 Al2s의 peak가 P-lite의 spectra에서도 관찰되었다(도 7). 따라서, PVP가 일라이트에 화학적으로 잘 결합되었음이 확인되었다.In order to find out whether PVP is well coated on the illite particles, FTIR and XPS were used for analysis. As a result, the amine peak of PVP was observed in the FTIR spectra of illite after PVP coating, and the peak corresponding to Si-O, the main component of illite, was observed at 970 cm -1 in spectra of all P-lite (FIG. 6) . In addition, N1s and C1s, compositions found only in PVP, were observed in the spectra of P-lite, and peaks of Si2s and Al2s, the main compositions of illite, were also observed in the spectra of P-lite (FIG. 7). Thus, it was confirmed that PVP was well chemically bonded to illite.
실시예 2. PVP 코팅 일라이트 마이크로 입자(P-lite)의 안정성 평가Example 2. Evaluation of stability of PVP-coated illite microparticles (P-lite)
2-1. 실험 방법2-1. Experiment method
동결 건조된 일라이트 및 P-lite를 PBS (phosphate-buffered saline)에 분산시키고, 37℃, 100rpm의 인큐베이터에서 0, 1, 2주간 보관한 후, 나노 입자의 크기 변화를 분석하였다. The freeze-dried illite and P-lite were dispersed in PBS (phosphate-buffered saline) and stored in an incubator at 37° C. and 100 rpm for 0, 1, and 2 weeks, and then the size change of nanoparticles was analyzed.
2-2. P-lite의 안정성 확인2-2. Check the stability of P-lite
동결건조 전, 후 일라이트와 P-lite의 크기를 비교한 결과, PBS에 분산시키는 경우 크기의 변화 없이 안정하게 존해자는 것으로 나타났다(도 8). 또한 분산 후 PBS 내에서 2주 동안 보관한 경우 P-lite2와 P-lite3는 크기가 작아진 반면, 일라이트와 P-lite1은 크기 변화 없이 안정한 것으로 확인되었다(도 9).As a result of comparing the size of illite and P-lite before and after lyophilization, it was found to remain stable without change in size when dispersed in PBS (FIG. 8). In addition, when stored in PBS for 2 weeks after dispersion, P-lite2 and P-lite3 decreased in size, while illite and P-lite1 were confirmed to be stable without size change (FIG. 9).
<실험예><Experimental example>
실험예 1. PVP 코팅 일라이트 마이크로 입자 활성산소제거능 분석Experimental Example 1. Analysis of active oxygen scavenging ability of PVP-coated illite microparticles
1-1. 실험 방법1-1. Experiment method
PVP 코팅 일라이트 마이크로 입자의 활성산소제거능 평가를 위하여, EDTA (0.1mM), FeCl3(0.1mM),H2O2(1mM)와 2-deoxy-D-ribose (3.75mM) 용액을 3차 증류수에 준비하고, 15ml conical tube에 100μl씩 순서대로 넣어준 후, 제조된 일라이트 또는 P-lite 입자들을 각각 1ml 첨가하였다. 이 때 negative control에는 H2O2와 마이크로 입자 용액 대신 3차 증류수를, positive control에는 마이크로 입자 대신 3차 증류수를 넣어주었다. 그 다음 0.5ml의 phosphate buffer (20mM)와 0.1ml의 ascorbic acid (0.1mM)를 첨가한 후, 37℃, 100rpm의 인큐베이터 안에서 1시간 동안 반응시켰다. 1ml의 2-thiobarbituric acid (1%w/v)와 1ml의 trichloroacetic acid (2%w/v)를 넣고 85℃의 water bath에서 15분간 중탕하여 반응을 종료시켰다. 반응 용액의 흡광도 (λ=535nm)를 microplate reader를 이용하여 분석하고, 하기의 식을 이용하여 활성산소제거능을 평가하였다.To evaluate the active oxygen scavenging ability of PVP-coated illite microparticles, EDTA (0.1mM), FeCl 3 (0.1mM), H 2 O 2 (1mM) and 2-deoxy-D-ribose (3.75mM) solutions were tertiary After preparing in distilled water and putting 100 μl in order in a 15 ml conical tube, 1 ml of each of the prepared illite or P-lite particles was added. At this time, tertiary distilled water was added to the negative control instead of H 2 O 2 and micro particle solution, and tertiary distilled water was added to the positive control instead of micro particle solution. Then, after adding 0.5ml of phosphate buffer (20mM) and 0.1ml of ascorbic acid (0.1mM), the mixture was reacted for 1 hour in an incubator at 37℃ and 100rpm. 1 ml of 2-thiobarbituric acid (1% w/v) and 1 ml of trichloroacetic acid (2% w/v) were added and the reaction was terminated by heating in a water bath at 85° C. for 15 minutes. The absorbance (λ = 535 nm) of the reaction solution was analyzed using a microplate reader, and the active oxygen scavenging ability was evaluated using the following formula.
1-2. P-lite의 항산화력 확인1-2. Confirmation of antioxidant activity of P-lite
도 10으로부터 알 수 있듯이, PVP 코팅 후 일라이트의 활성산소제거 능력이 크게 향상된 것으로 나타났다. 일라이트의 경우 10% 미만의 아주 낮은 항산화력을 보였으나 P-lite 입자들은 50% 이상의 활성산소제거능을 나타내었으며 특히, P-lite1의 경우 약 80%의 항산화력을 나타내는 것으로 확인되었다. As can be seen from FIG. 10, the active oxygen removal ability of illite was greatly improved after PVP coating. Illite showed a very low antioxidant power of less than 10%, but P-lite particles showed an active oxygen removal ability of more than 50%, and in particular, it was confirmed that P-lite1 showed an antioxidant power of about 80%.
실험예 2. PVP 코팅 일라이트 마이크로 입자 항균성 분석Experimental Example 2. Analysis of antibacterial activity of PVP-coated illite microparticles
2-1. 실험 방법2-1. Experiment method
실험에 사용된 균주인 황색포도상구균 (S.aureus)는 Luria-Bertani broth (LB broth) 액체배치에 37℃에서 배양되었다. 24시간 배양된 균액을 새 LB broth 액체배지에 접종하여 흡광도 (600nm)가 0.1이 되도록 농도를 조정한 후 P-lite 용액 (0.5mg/ml)을 첨가하였다. 실험 균주를 다시 37℃에서 24시간 배양한 뒤 희석 후 LB broth 배지에 Agar를 첨가해 준비한 고체 배지에 100μl씩 분주하였다. 5~6개의 유리 bead를 이용하여 고체 배지 위 실험 균주를 균일하게 깔아준 뒤 37℃의 인큐베이터 내에서 24시간 배양하였다. 그 후 생성된 colony를 counting하여 P-lite의 항균력을 평가하였다.The strain used in the experiment, Staphylococcus aureus ( S. aureus ), was cultured at 37° C. in a Luria-Bertani broth (LB broth) broth. The bacterial solution cultured for 24 hours was inoculated into a new LB broth liquid medium, the absorbance (600 nm) was adjusted to a concentration of 0.1, and then a P-lite solution (0.5 mg/ml) was added. After culturing the experimental strain again at 37 ° C. for 24 hours, after dilution, 100 μl of each was dispensed into a solid medium prepared by adding Agar to the LB broth medium. After uniformly spreading the test strain on the solid medium using 5 to 6 glass beads, it was cultured for 24 hours in an incubator at 37 ° C. After that, the generated colony was counted to evaluate the antibacterial activity of P-lite.
2-2. P-lite의 항균 활성 확인2-2. Confirmation of antibacterial activity of P-lite
도 11로부터 알 수 있듯이, PVP 코팅 후 일라이트의 항균성이 크게 향상된 것으로 나타났다. 특히, P-lite1을 처리한 경우 S.aureus의 생존율이 30% 이하 까지 낮아지는 것으로 확인되었다.As can be seen from Figure 11, it was found that the antibacterial properties of illite significantly improved after PVP coating. In particular, it was confirmed that the survival rate of S. aureus was lowered to 30% or less when treated with P-lite1.
실시예들을 중심으로 살펴보았다. 본 발명이 속하는 기술 분야에서 통상의 지식을 가진 자는 본 발명이 본 발명의 본질적인 특성에서 벗어나지 않는 범위에서 변형된 형태로 구현될 수 있음을 이해할 수 있을 것이다. 그러므로 개시된 실시예들은 한정적인 관점이 아니라 설명적인 관점에서 고려되어야 한다. 본 발명의 범위는 전술한 설명이 아니라 특허청구범위에 나타나 있으며, 그와 동등한 범위 내에 있는 모든 차이점은 본 발명에 포함된 것으로 해석되어야 할 것이다.It was looked at based on the embodiments. Those skilled in the art to which the present invention pertains will be able to understand that the present invention can be implemented in a modified form without departing from the essential characteristics of the present invention. Therefore, the disclosed embodiments should be considered from an illustrative rather than a limiting point of view. The scope of the present invention is shown in the claims rather than the foregoing description, and all differences within the equivalent scope will be construed as being included in the present invention.
Claims (15)
A polyvinylpyrrolidone-coated illite microparticle containing polyvinylpyrrolidone (PVP) and illite in a weight ratio of 1:1 to 1:20, with improved water dispersibility.
상기 폴리비닐파이롤리돈의 분자량은 10kDa인 것을 특징으로 하는 것인, 수분산성이 향상된 폴리비닐파이롤리돈 코팅 일라이트 마이크로 입자.
According to claim 1,
Polyvinylpyrrolidone coated illite microparticles with improved water dispersibility, characterized in that the molecular weight of the polyvinylpyrrolidone is 10 kDa.
상기 폴리비닐파이롤리돈 코팅 일라이트 마이크로 입자의 크기는 4μm 내지 9μm인 것을 특징으로 하는 것인, 수분산성이 향상된 폴리비닐파이롤리돈 코팅 일라이트 마이크로 입자.
According to claim 1,
Polyvinylpyrrolidone-coated illite microparticles with improved water dispersibility, characterized in that the size of the polyvinylpyrrolidone-coated illite microparticles is 4 μm to 9 μm.
A cosmetic composition for preventing or improving symptoms or diseases caused by active oxygen, comprising the polyvinylpyrrolidone-coated illite micro-particles according to any one of claims 1 to 3 as an active ingredient.
상기 활성산소로 유발되는 증상 또는 질환은 피부노화, 주름생성, 피부색소침착, 아토피, 여드름, 건선 또는 습진인 것을 특징으로 하는 것인, 화장료 조성물. According to claim 4,
Symptoms or diseases caused by the active oxygen are skin aging, wrinkle formation, skin pigmentation, atopy, acne, psoriasis or eczema, characterized in that the cosmetic composition.
상기 화장료는 앰플, 크림, 로션, 화장수, 에센스 또는 팩의 형태로 제조되는 것을 특징으로 하는 것인, 화장료 조성물.
According to claim 5,
The cosmetic composition is characterized in that it is prepared in the form of an ampoule, cream, lotion, lotion, essence or pack.
A pharmaceutical composition for preventing or treating symptoms or diseases caused by active oxygen, comprising the polyvinylpyrrolidone-coated illite microparticles according to any one of claims 1 to 3 as an active ingredient.
상기 활성산소 과잉생성으로 인해 유발되는 질환은 뇌졸중, 파킨슨병, 알츠하이머병, 노화, 심장질환, 허혈, 동맥경화, 피부질환, 염증, 관절염, 류마티스 관절염, 자가면역질환, 고지혈증, 간질환, 당뇨병, 암, 만성궤양, 화상 또는 창상인 것을 특징으로 하는 것인, 약제학적 조성물.
According to claim 7,
Diseases caused by excessive production of reactive oxygen species include stroke, Parkinson's disease, Alzheimer's disease, aging, heart disease, ischemia, arteriosclerosis, skin disease, inflammation, arthritis, rheumatoid arthritis, autoimmune disease, hyperlipidemia, liver disease, diabetes, Cancer, chronic ulcers, burns or wounds characterized in that, the pharmaceutical composition.
A quasi-drug composition for preventing or treating symptoms or diseases caused by active oxygen, comprising the polyvinylpyrrolidone-coated illite microparticles according to any one of claims 1 to 3 as an active ingredient.
상기 활성산소 과잉생성으로 인해 유발되는 질환은 뇌졸중, 파킨슨병, 알츠하이머병, 노화, 심장질환, 허혈, 동맥경화, 피부질환, 염증, 관절염, 류마티스 관절염, 자가면역질환, 고지혈증, 간질환, 당뇨병, 암, 만성궤양, 화상 또는 창상인 것을 특징으로 하는 것인, 의약외품 조성물.
According to claim 9,
Diseases caused by excessive production of reactive oxygen species include stroke, Parkinson's disease, Alzheimer's disease, aging, heart disease, ischemia, arteriosclerosis, skin disease, inflammation, arthritis, rheumatoid arthritis, autoimmune disease, hyperlipidemia, liver disease, diabetes, Cancer, chronic ulcers, burns or wounds, characterized in that the quasi-drug composition.
A food composition for preventing or improving symptoms or diseases caused by active oxygen, comprising the polyvinylpyrrolidone-coated illite microparticles according to any one of claims 1 to 3 as an active ingredient.
상기 식품은 육류, 소세지, 빵, 쵸코렛, 캔디류, 스넥류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 차, 드링크제, 알콜 음료 또는 비타민 복합제인 것을 특징으로 하는 것인, 식품 조성물.
According to claim 11,
The food is meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, other noodles, gum, dairy products including ice cream, various soups, beverages, tea, drinks, alcoholic beverages or vitamin complexes. To be, a food composition.
An antibacterial composition comprising the polyvinylpyrrolidone-coated illite microparticles according to any one of claims 1 to 3 having improved water dispersibility as an active ingredient.
상기 항균 조성물은 스타필로코커스(Staphylococcus) 속, 바실러스(Bacillus) 속, 슈도모나스(Pseudomonas) 속, 칸디다(Candida) 속, 프로피오니박테리움(Propionibacterium) 속, 스트렙토코커스(Streptococcus) 속, 프로테우스(Proteus) 속, 코리네박테리움(Corynebacterium) 속, 엔테로코커스(Enterococcus) 속, 클렙시엘라(Klebsiella) 속 및 대장균(Escherichia coli)에 항균 활성을 나타내는 것을 특징으로 하는 것인, 항균 조성물.
According to claim 13,
The antibacterial composition is Staphylococcus genus, Bacillus genus, Pseudomonas genus, Pseudomonas genus, Candida genus, Propionibacterium genus, Streptococcus genus, Proteus genus genus, Corynebacterium genus, Enterococcus genus, Klebsiella genus, Klebsiella genus and E. coli ( Escherichia coli ), characterized in that exhibiting antibacterial activity against, the antibacterial composition.
상기 항균 조성물은 의료기구, 건설/건축 자재, 자동차 부품, 선박 부품, 철도 부품, 스포츠 용품 또는 완구 용품에 사용되는 것을 특징으로 하는 것인, 항균 조성물.
According to claim 13,
The antibacterial composition is characterized in that used for medical devices, construction / building materials, automobile parts, ship parts, railway parts, sports goods or toy goods, antimicrobial composition.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210056555A KR102581709B1 (en) | 2021-04-30 | 2021-04-30 | Illite microparticles coated with polyvinylpyrrolidone having improved water dispersibility, preparation method thereof and use thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210056555A KR102581709B1 (en) | 2021-04-30 | 2021-04-30 | Illite microparticles coated with polyvinylpyrrolidone having improved water dispersibility, preparation method thereof and use thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20220150448A true KR20220150448A (en) | 2022-11-11 |
| KR102581709B1 KR102581709B1 (en) | 2023-09-25 |
Family
ID=84042935
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210056555A KR102581709B1 (en) | 2021-04-30 | 2021-04-30 | Illite microparticles coated with polyvinylpyrrolidone having improved water dispersibility, preparation method thereof and use thereof |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR102581709B1 (en) |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070038938A (en) * | 2006-11-20 | 2007-04-11 | 이민화 | Anti-microbial yarn, antifungal yarn, anti-microbial(anti-bacterial) perfume yarn, antifungal perfume yarn and their manufacturing method |
| KR20120118033A (en) * | 2010-01-14 | 2012-10-25 | 바스프 에스이 | Water-resistant cosmetic formulations comprising a hydrophobically modified vinylpyrrolidone copolymer |
| KR101262967B1 (en) | 2011-05-23 | 2013-05-10 | 충남대학교산학협력단 | Method for improving dispersibility of illite in polymer |
| KR20200104465A (en) * | 2019-02-26 | 2020-09-04 | 한국세라믹기술원 | Prussian blue/chitosan nanoparticle complexes for removing reactive oxygen species and its uses |
| KR102197866B1 (en) * | 2020-06-25 | 2021-01-04 | 박성율 | Composition of cosmetic application containing illite eluate for inhibiting secretion of sebum, treating acne or soothing skin |
-
2021
- 2021-04-30 KR KR1020210056555A patent/KR102581709B1/en active IP Right Grant
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20070038938A (en) * | 2006-11-20 | 2007-04-11 | 이민화 | Anti-microbial yarn, antifungal yarn, anti-microbial(anti-bacterial) perfume yarn, antifungal perfume yarn and their manufacturing method |
| KR20120118033A (en) * | 2010-01-14 | 2012-10-25 | 바스프 에스이 | Water-resistant cosmetic formulations comprising a hydrophobically modified vinylpyrrolidone copolymer |
| KR101262967B1 (en) | 2011-05-23 | 2013-05-10 | 충남대학교산학협력단 | Method for improving dispersibility of illite in polymer |
| KR20200104465A (en) * | 2019-02-26 | 2020-09-04 | 한국세라믹기술원 | Prussian blue/chitosan nanoparticle complexes for removing reactive oxygen species and its uses |
| KR102197866B1 (en) * | 2020-06-25 | 2021-01-04 | 박성율 | Composition of cosmetic application containing illite eluate for inhibiting secretion of sebum, treating acne or soothing skin |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102581709B1 (en) | 2023-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Li et al. | The simultaneous loading of catechin and quercetin on chitosan-based nanoparticles as effective antioxidant and antibacterial agent | |
| Hosseinnia et al. | Optimization of Ziziphora clinopodiodes essential oil microencapsulation by whey protein isolate and pectin: A comparative study | |
| KR102251184B1 (en) | Prussian blue/chitosan nanoparticle complexes for removing reactive oxygen species and its uses | |
| JP5462430B2 (en) | Anti-inflammatory and analgesic | |
| Manne et al. | Pterocarpus marsupium Roxb. heartwood extract synthesized chitosan nanoparticles and its biomedical applications | |
| JP6452104B2 (en) | Fibronectin expression promoter | |
| JP2012036128A (en) | Collagen production promoter and skin-beautifying composition comprising the same | |
| KR102419736B1 (en) | Pluronic polymer/prussian blue nanoparticle complexes for removing reactive oxygen species and its uses | |
| JP2006265219A (en) | Diet composition | |
| KR102581709B1 (en) | Illite microparticles coated with polyvinylpyrrolidone having improved water dispersibility, preparation method thereof and use thereof | |
| KR20220165306A (en) | Prussian blue/polyvinylpyrrolidone nanoparticle complex and its use | |
| JP2022027422A (en) | Food composition for immunostimulation and immunostimulation agent | |
| EP3936575A1 (en) | Surface-treated inorganic particles, manufacturing method of the same, dispersion solution of the same, and cosmetic composition including the same | |
| KR20230146433A (en) | Nanoparticles encapsulating antibacterial peptides with chitosan, and use thereof | |
| Hsieh et al. | Development and evaluation of functional nanoemulsion gel using eco-friendly fucoidan for drug delivery applications | |
| JP2008074802A (en) | Skin-beautifying composition | |
| JP2010018584A (en) | COSMETIC COMPOSITION CONTAINING POLY-gamma-L-GLUTAMIC ACID AND/OR ITS SALT | |
| JP2009107957A (en) | Water-retaining composition | |
| KR102668029B1 (en) | Phytoncide-loaded polyvinylpyrrolidone micelle, method for preparing the same and the use thereof | |
| KR20210031555A (en) | Nanocapsule coated with chitosan comprising retinol or retinol derivatives and uses thereof | |
| KR102303334B1 (en) | Coating method of strain for cosmetic composition, coated strain by the method and its use | |
| KR20240002269A (en) | Rhamnolipid-coated Prussian blue nanoparticles complex having anti-oxidative and antimicrobial activity and its uses | |
| JP2009120517A (en) | Intestinal flora improver | |
| KR102316264B1 (en) | Method for improving water-dispersibility of natural fullerene with amphiphilic polymers and use of natural fullerene prepared thereby | |
| JP2011105607A (en) | Agent for inhibiting allergic reaction late phase, comprising biosurfactant as active ingredient |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |